A Phase 2, Single Arm, Multicenter, Open-label Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Zanubrutinib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors BeiGene
- 05 Dec 2018 Planned End Date changed from 30 Apr 2019 to 24 Aug 2019.
- 05 Dec 2018 Planned primary completion date changed from 15 Oct 2018 to 24 May 2019.
- 05 Dec 2018 Status changed from recruiting to active, no longer recruiting.